Zion (Solid Tumors)

Purpose of this Study

We are doing this study to find out what the safest and most effective dose of the study drug (ZN-A-1041) is when given alone or in combination with Capecitabine.

Who Can Participate?

Eligibility

Phase 1a - Adults with HER2-positive advanced solid tumors
Phase 1b - Adults with HER2-positive breast cancer
Phase 1c - Adults with HER2-positive unresectable or metastatic breast cancer with brain metastases

What is Involved?

This study will consist of three groups, Group 1a, Group 1b, and Group 1c.

Group 1a is for people with HER2-positive advanced solid tumors and will get the study drug, ZN-A-1041

Group 1b is for people with HER2-positive breast cancer and will get the study drug in combination with Capecitabine

Group 1c if for people with HER2-positive unresectable or metastatic breast cancer with brain metastases and will get the study drug in combination with Capecitabine

If you choose to join this study you will:
-Complete a 28 day screening period
-Complete a 21 day period where you take the study drug twice a day
-Have physical exams, blood and urine tests
-Have an eye exam
-Have imaging scans (CT and/or MRI)
-Complete a follow-up 28 days after finishing the study drug

You will be in the study until your disease progresses or you're unable to tolerate the study drug(s).

Study Details

Full Title

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients with HER2-Positive Advanced Solid Tumors

Principal Investigator

Carey
Anders

Protocol Number

PRO00105701

NCT ID

NCT05593094

Phase

I

Enrollment Status

OPEN TO ACCRUAL